Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Pipeline Insight

DelveInsight’s, “Chimeric Antigen Receptor T-Cell Therapy Pipeline Insight 2026” report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in Chimeric Antigen Receptor T-Cell Therapy (CAR-T) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

•   Global coverage

Chimeric Antigen Receptor T-Cell Therapy Disease Understanding

Chimeric Antigen Receptor T-Cell Therapy Overview

Chimeric Antigen Receptor T-cell (CAR-T) therapy is an advanced form of immunotherapy in which a patient’s own T cells are collected, genetically modified to express chimeric antigen receptors that recognize specific cancer antigens, expanded in the laboratory, and reinfused into the patient to target and eliminate malignant cells. This strategy enhances the natural ability of T cells to identify and destroy tumor cells in an antigen-specific manner, independent of major histocompatibility complex (MHC) presentation, thereby overcoming key mechanisms of tumor immune evasion. It represents a personalized and highly targeted therapeutic approach in oncology.

CAR-T therapy is primarily indicated for the treatment of relapsed or refractory hematologic malignancies, particularly B-cell cancers such as B-cell acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma, mantle cell lymphoma, and multiple myeloma. These therapies are generally used in patients who have failed multiple lines of standard treatments. Ongoing clinical research is expanding its potential use into earlier lines of therapy and into solid tumors, although its current approved indications remain largely within hematological cancers.

CAR-T therapy is associated with significant and potentially life-threatening toxicities. The most common complication is cytokine release syndrome (CRS), a systemic inflammatory response characterized by fever, hypotension, hypoxia, and organ dysfunction due to massive cytokine release from activated immune cells. Another major toxicity is immune effector cell-associated neurotoxicity syndrome (ICANS), which can present with confusion, aphasia, seizures, or cerebral edema. Additional complications include infections, prolonged cytopenias, hypogammaglobulinemia, and tumor lysis syndrome, necessitating careful monitoring and specialized management.

CAR-T therapy has significant clinical importance as it has revolutionized the treatment landscape for certain refractory and relapsed cancers by achieving high remission rates in patients with otherwise limited therapeutic options. It offers the potential for durable and long-lasting responses due to the persistence and expansion of engineered T cells within the body. This therapy has shifted the paradigm toward personalized medicine in oncology, although challenges such as high cost, limited accessibility, manufacturing complexity, and management of toxicities remain areas of ongoing research and development.

"Chimeric Antigen Receptor T-Cell Therapy Pipeline Insight 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chimeric Antigen Receptor T-Cell Therapy (CAR-T) pipeline landscape is provided which includes the disease overview and Chimeric Antigen Receptor T-Cell Therapy (CAR-T) treatment guidelines. The assessment part of the report embraces, in depth Chimeric Antigen Receptor T-Cell Therapy (CAR-T) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chimeric Antigen Receptor T-Cell Therapy (CAR-T) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Chimeric Antigen Receptor T-Cell Therapy Pipeline Report Highlights

• The Chimeric Antigen Receptor T-Cell Therapy companies and academics are working to assess challenges and seek opportunities that could influence Chimeric Antigen Receptor T-Cell Therapy (CAR-T) R&D. The therapies under development are focused on novel approaches to treat/improve Chimeric Antigen Receptor T-Cell Therapy (CAR-T). 

Chimeric Antigen Receptor T-Cell Therapy Emerging Drugs Analysis

This segment of the Chimeric Antigen Receptor T-Cell Therapy (CAR-T) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chimeric Antigen Receptor T-Cell Therapy Emerging Drugs

Descartes-08: Cartesian Therapeutics

Descartes-08 is a potential first-in-class autologous mRNA-engineered chimeric antigen receptor T-cell (mRNA CAR-T) therapy designed for autoimmune diseases, it uses a patient’s own T cells that are transiently modified with mRNA to express a CAR targeting B-cell maturation antigen (BCMA), thereby selectively depleting pathogenic B cells responsible for autoantibody production without requiring preconditioning chemotherapy or posing risks of genomic integration seen with DNA-based CAR-T therapies. Mechanistically, by targeting BCMA-expressing B cells, Descartes-08 aims to suppress abnormal immune responses driving diseases such as myasthenia gravis and systemic lupus erythematosus. The drug is primarily being developed for generalized myasthenia gravis, with additional clinical development in systemic lupus erythematosus and myositis (including juvenile dermatomyositis). It has received multiple regulatory designations from the U.S. FDA, including Regenerative Medicine Advanced Therapy (RMAT) designation and Orphan Drug designation for myasthenia gravis, as well as Rare Pediatric Disease designation for juvenile dermatomyositis. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Myasthenia Gravis.

Rondecabtagene autoleucel: Lyell Immunopharma, Inc.

Rondecabtagene autoleucel (also known as ronde-cel or LYL314) is an investigational next-generation autologous chimeric antigen receptor (CAR) T-cell therapy in which a patient’s own T cells are engineered to target cancer cells, specifically, it is a dual-targeting CD19/CD20 CAR-T product designed to improve response durability in B-cell malignancies. The therapy is being developed primarily for relapsed or refractory large B-cell lymphoma (including diffuse large B-cell lymphoma) across second-line and third-or-later-line treatment settings. It has received multiple U.S. FDA designations, including Regenerative Medicine Advanced Therapy (RMAT), Fast Track designation, and Orphan Drug designation for certain lymphoma subtypes. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Relapsed or Refractory Large B-Cell Lymphoma.

WU-CART-007: Wugen, Inc.

WU-CART-007 is an allogeneic chimeric antigen receptor T-cell (CAR-T) therapy composed of healthy donor-derived T cells that are genetically engineered using CRISPR/Cas9 technology, representing its structural design as a fratricide-resistant, CD7-targeted CAR-T cell product. The therapy targets CD7-expressing malignant T cells and incorporates deletion of CD7 and the T-cell receptor alpha constant (TRAC) genes to prevent CAR-T cell self-killing (fratricide) and reduce the risk of graft-versus-host disease, thereby enabling effective anti-tumor activity against CD7+ hematologic malignancies. It is primarily being developed for the treatment of relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL). The drug has received multiple regulatory designations from the U.S. FDA and international agencies, including Fast Track, Orphan Drug, Rare Pediatric Disease, and Regenerative Medicine Advanced Therapy (RMAT) designations, as well as PRIME designation in the European Union. Currently, the drug is being evaluated in the Phase II stage of its development.

TX200: Sangamo Therapeutics

TX200, developed by Sangamo Therapeutics, is an investigational autologous chimeric antigen receptor regulatory T-cell (CAR-Treg) therapy in which a patient’s own regulatory T cells (Tregs) are genetically engineered to express a CAR targeting the HLA-A2 antigen, representing its structure as a personalized, gene-edited cell therapy product. Mechanistically, TX200 is designed to localize to a transplanted kidney expressing HLA-A2 and, upon antigen binding, suppress local immune responses, reduce inflammation, and promote immunological tolerance, thereby preventing immune-mediated graft rejection and potentially reducing the need for lifelong immunosuppressive therapy. The therapy is being developed for use in patients undergoing HLA-A2 mismatched kidney transplantation (solid organ transplantation), particularly to prevent rejection in end-stage renal disease patients receiving donor kidneys. TX200 has received Orphan Medicinal Product Designation from the European Commission for solid organ transplantation. Currently, the drug is being evaluated in the Phase I/II stage of its development.

A2B395: A2 Biotherapeutics

A2B395 is an investigational allogeneic logic-gated chimeric antigen receptor T-cell (CAR-T) therapy built using the company’s proprietary Tmod™ platform, in which donor-derived T cells are engineered with both an activator receptor targeting epidermal growth factor receptor (EGFR) and a blocker receptor recognizing HLA-A02, representing its unique dual-receptor structural design. A2B395 selectively kills EGFR-expressing tumor cells that have lost HLA-A02 expression (loss of heterozygosity), while the HLA-A02-directed inhibitory receptor functions as a safety switch to prevent damage to normal healthy cells that retain HLA-A02, thereby improving tumor selectivity and reducing off-target toxicity. The therapy is being developed for multiple solid tumor indications, including colorectal cancer, non-small cell lung cancer, triple-negative breast cancer, head and neck squamous cell carcinoma, renal cell carcinoma, cholangiocarcinoma, and other EGFR-expressing malignancies. Currently, the drug is being evaluated in the Phase I/II stage of its development.

ALLO-329: Allogene Therapeutics

ALLO-329 is an investigational next-generation allogeneic dual-targeted CD19/CD70 chimeric antigen receptor T-cell (AlloCAR-T) therapy designed for autoimmune diseases. it uses CRISPR-based site-specific gene editing to engineer donor-derived T cells that simultaneously target CD19-positive B cells and CD70-positive activated T cells, thereby addressing both B-cell and T-cell dysfunction that drive autoimmune pathogenesis, while incorporating proprietary Dagger® technology to enhance CAR-T expansion, prevent rejection, and potentially reduce or eliminate the need for lymphodepletion. The therapy is being developed for multiple autoimmune indications including systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (such as dermatomyositis), and systemic sclerosis (scleroderma). ALLO-329 has received multiple U.S. FDA Fast Track designations for autoimmune conditions. Currently, the drug is being evaluated in the Phase I stage of its development.

Further product details are provided in the report……..

Chimeric Antigen Receptor T-Cell Therapy Drug Therapeutic Assessment

This segment of the report provides insights about the different Chimeric Antigen Receptor T-Cell Therapy (CAR-T) drugs segregated based on following parameters that define the scope of the report, such as:

Major Chimeric Antigen Receptor T-Cell Therapy Players in Chimeric Antigen Receptor T-Cell Therapy  

There are approx. 180+ key companies which are developing the therapies Chimeric Antigen Receptor T-Cell Therapy (CAR-T). The companies which have their Chimeric Antigen Receptor T-Cell Therapy (CAR-T) drug candidates in the most advanced stage, i.e. Phase III include, Cartesian Therapeutics, and others.

Chimeric Antigen Receptor T-Cell Therapy Clinical Trial Phases

DelveInsight’s report covers around 200+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Chimeric Antigen Receptor T-Cell Therapy Drug Route of Administration

Chimeric Antigen Receptor T-Cell Therapy (CAR-T) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Chimeric Antigen Receptor T-Cell Therapy Product Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Chimeric Antigen Receptor T-Cell Therapy Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chimeric Antigen Receptor T-Cell Therapy Clinical Trial Activities

The Chimeric Antigen Receptor T-Cell Therapy Pipeline report provides insights into Chimeric Antigen Receptor T-Cell Therapy Clinical Trials within phase II, I, preclinical and discovery stage. It also analyses Chimeric Antigen Receptor T-Cell Therapy (CAR-T) therapeutic drugs key players involved in developing key drugs. 

Chimeric Antigen Receptor T-Cell Therapy Pipeline Development Activities

The Chimeric Antigen Receptor T-Cell Therapy Clinical Trial analysis report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chimeric Antigen Receptor T-Cell Therapy (CAR-T) drugs.

Chimeric Antigen Receptor T-Cell Therapy Pipeline Report Insights

• Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Chimeric Antigen Receptor T-Cell Therapy Pipeline Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions Answered In The Chimeric Antigen Receptor T-Cell Therapy Pipeline Report

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Chimeric Antigen Receptor T-Cell Therapy (CAR-T) drugs?
• How many Chimeric Antigen Receptor T-Cell Therapy (CAR-T) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chimeric Antigen Receptor T-Cell Therapy (CAR-T)?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chimeric Antigen Receptor T-Cell Therapy (CAR-T) therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Chimeric Antigen Receptor T-Cell Therapy (CAR-T) and their status?
• What are the key designations that have been granted to the emerging drugs?

Chimeric Antigen Receptor T-Cell Therapy Key Companies

• Cartesian Therapeutics
• Lyell Immunopharma, Inc.
• AstraZeneca
• Kyverna Therapeutics
• Wugen, Inc
• Biomedicine GmbH
• A2 Biotherapeutics Inc.
• Allogene Therapeutics
• Juventas Cell Therapy Ltd.
• Cellectis S.A.
• Sangamo Therapeutics
• Shenzhen Celconta Life Science Co., Ltd.
• Regeneron Pharmaceuticals
• Guangzhou FineImmune Biotechnology Co., LTD.
• ZhongQi Pharmaceutical Technology Co., Ltd.
• Arc ellx, Inc.
• Therorna
• Wondercel Biotech
• CARsgen Therapeutics Co., Ltd.
• Immunochina Medical Science & Technology Co., Ltd.
• Beijing Immunochina Medical Science & Technology Co., Ltd.

Chimeric Antigen Receptor T-Cell Therapy Key Products

• Descartes-08
• Rondecabtagene autoleucel
• AZD0120
• KYV-101
• WU-CART-007
• MB-CART2019.1
• Miltenyi
• A2B395
• ALLO-329
• CNCT19
• UCART22
• TX200
• XKDCT225
• 27T51
• Super CAR-T
• SYS6020 CSPC
• anito-cel
• TI-0032-III
• UWD-00B
• CT071
• CT011
• IM19
• WL276